TORONTO, CANADA--(Marketwire - June 14, 2012) - Soricimed Biopharma Inc., a private company developing novel cancer therapeutics and diagnostics, will be exhibiting with the Atlantic Canada Bio-industries Alliance (booth #735) at 2012 BIO International Convention, taking place at the Boston Convention & Exhibition Centers, June 18-21.
Soricimed recently announced that they have received IND clearance to commence human trial of their new anti-cancer drug, SOR-C13. SOR-C13 is a peptide that inhibits the non-voltage gated calcium channel (TRPV6) found in epithelial cancers such as ovarian, breast, prostate and others. Pre-clinical studies have shown that SOR-C13 induces apoptosis (cell death), inhibits cell proliferation and reduces tumor volume while minimizing side effects associated with typical chemotherapy. Soricimed will also be discussing its blood test to detect early cancers, and its novel drug delivery system.
Paul Gunn, President & CEO of Soricimed Biopharma commented, "2012 BIO comes at an extremely timely juncture in Soricimed's development. As the premiere go-to convention for BIO innovators, it will provide an ideal opportunity to meet with key players in a position to partner with Soricimed as it moves forward into the next major phase in the development and commercialization of SOR-C13 ".
Anyone interested in meeting with Soricimed's executives, can contact them through the 2012 BIO One-on-One Partnering system available on 2012 BIO's website.
ABOUT SORICIMED BIOPHARMA
Soricimed Biopharma Inc. is a private drug and diagnostic development company created in 2005 by Professor Jack Stewart and Paul Gunn following the discovery and development of a proprietary peptide, soricidin. Soricidin is the basis for Soricimed Biopharma Inc.'s targeted cancer management program focused on cancer therapeutics and diagnostics. Using focused innovative strategies in collaboration with major world-class cancer research institutions, Soricimed's drugs have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in various classic animal and in vitro tumour models. Privately held, Soricimed is funded through private investors and various programs from the Government of Canada. For more information visit, www.soricimed.com
Contact Information:
Partner, Hageman Communications
416-951-7988
Julie.fotheringham@hageman.ca
www.soricimed.com